18 March 2015Americas

Delaware court rules on claim construction in Banzel patent row

A US district court yesterday (March 17) gave its opinion on how a group of disputed patent claims must be construed in a patent infringement case between Eisai and Novartis and several generic drug makers.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

10x Genomics settles suit with rival and targets DNA sequencing startup

12 May 2026 The dominant player in the spatial biology market has sued a San Diego-based life sciences company over its genetic analysis technology, as another lawsuit in its patent litigation campaign approaches conclusion.

Americas

Trade secrets, AI and the new scrutiny of big damages awards

11 May 2026 Trade secret filings in the US reached an all-time high in 2025—particularly those relating to AI. Jeff Farrow of Michelman Robinson explains the principles that courts are increasingly applying, and how companies on both sides of the ‘v’ can prepare.

Americas

WATCH: Interview with Mythili Markowski, director at Regeneron

8 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.